1. Home
  2. HAFC vs ESPR Comparison

HAFC vs ESPR Comparison

Compare HAFC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hanmi Financial Corporation

HAFC

Hanmi Financial Corporation

HOLD

Current Price

$29.60

Market Cap

821.2M

Sector

Finance

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.13

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAFC
ESPR
Founded
1982
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
821.2M
731.9M
IPO Year
2000
2013

Fundamental Metrics

Financial Performance
Metric
HAFC
ESPR
Price
$29.60
$3.13
Analyst Decision
Hold
Strong Buy
Analyst Count
3
4
Target Price
$32.17
$8.75
AVG Volume (30 Days)
228.5K
17.5M
Earning Date
04-21-2026
05-07-2026
Dividend Yield
3.75%
N/A
EPS Growth
22.44
60.71
EPS
0.75
N/A
Revenue
$270,165,000.00
$403,135,000.00
Revenue This Year
$18.65
N/A
Revenue Next Year
$7.28
$12.81
P/E Ratio
$38.71
N/A
Revenue Growth
15.28
21.31
52 Week Low
$21.84
$0.76
52 Week High
$31.33
$4.18

Technical Indicators

Market Signals
Indicator
HAFC
ESPR
Relative Strength Index (RSI) 54.51 70.78
Support Level $29.20 $2.37
Resistance Level $30.47 $3.18
Average True Range (ATR) 0.66 0.04
MACD -0.21 0.05
Stochastic Oscillator 31.58 96.38

Price Performance

Historical Comparison
HAFC
ESPR

About HAFC Hanmi Financial Corporation

Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: